ATE481504T1 - Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderung - Google Patents
Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderungInfo
- Publication number
- ATE481504T1 ATE481504T1 AT05815265T AT05815265T ATE481504T1 AT E481504 T1 ATE481504 T1 AT E481504T1 AT 05815265 T AT05815265 T AT 05815265T AT 05815265 T AT05815265 T AT 05815265T AT E481504 T1 ATE481504 T1 AT E481504T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer
- malignant neoplasia
- taxan
- predicting
- response
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 230000003211 malignant effect Effects 0.000 title abstract 2
- 230000009826 neoplastic cell growth Effects 0.000 title abstract 2
- 238000012239 gene modification Methods 0.000 title 1
- 230000005017 genetic modification Effects 0.000 title 1
- 235000013617 genetically modified food Nutrition 0.000 title 1
- 229940123237 Taxane Drugs 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 3
- 206010006187 Breast cancer Diseases 0.000 abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract 2
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04029323 | 2004-12-10 | ||
| PCT/EP2005/013141 WO2006061216A2 (en) | 2004-12-10 | 2005-12-08 | Genetic alteration useful for the response prediction of malignant neoplasia to taxane-based medical treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE481504T1 true ATE481504T1 (de) | 2010-10-15 |
Family
ID=34927727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05815265T ATE481504T1 (de) | 2004-12-10 | 2005-12-08 | Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderung |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090215036A1 (de) |
| EP (1) | EP1824997B1 (de) |
| JP (1) | JP2008524986A (de) |
| AT (1) | ATE481504T1 (de) |
| DE (1) | DE602005023646D1 (de) |
| WO (1) | WO2006061216A2 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2445204C (en) | 2002-10-16 | 2014-08-12 | Streck Laboratories, Inc. | Method and device for collecting and preserving cells for analysis |
| EP1954837A4 (de) * | 2005-11-28 | 2009-11-04 | Siemens Healthcare Diagnostics | Kinetischer pcr-test zur quantifizierung der genamplifikation auf chromosom 17 |
| WO2008115561A2 (en) * | 2007-03-21 | 2008-09-25 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
| WO2009021338A1 (en) * | 2007-08-15 | 2009-02-19 | UNIVERSITé DE SHERBROOKE | Alternative splicing gene variants in cancer detection |
| FR2928657B1 (fr) * | 2008-03-14 | 2013-12-20 | Chu Saint Etienne Chu Hopital Nord | Methode, procede, et kit de diagnostic, pronostic, suivi d'un cancer |
| US11634747B2 (en) | 2009-01-21 | 2023-04-25 | Streck Llc | Preservation of fetal nucleic acids in maternal plasma |
| DK2398912T3 (en) | 2009-02-18 | 2017-10-30 | Streck Inc | Conservation of cell-free nucleic acids |
| JP2013510580A (ja) * | 2009-11-12 | 2013-03-28 | エソテリックス ジェネティック ラボラトリーズ， エルエルシー | 遺伝子座のコピー数の分析 |
| JP5497423B2 (ja) * | 2009-12-25 | 2014-05-21 | 東京エレクトロン株式会社 | 成膜装置 |
| WO2012095378A1 (en) | 2011-01-11 | 2012-07-19 | Roche Diagnostics Gmbh | High resolution melting analysis as a prescreening tool |
| CA2852098C (en) * | 2011-10-21 | 2023-05-02 | Chronix Biomedical | Colorectal cancer associated circulating nucleic acid biomarkers |
| DK3225699T3 (da) * | 2012-02-13 | 2020-12-21 | Streck Inc | Blodopsamlingsanordning til forbedret nukleinsyreregulering |
| ES2938048T3 (es) | 2013-07-24 | 2023-04-04 | Streck Llc | Composiciones y procedimientos para estabilizar las células tumorales circulantes |
| KR101874390B1 (ko) * | 2013-09-26 | 2018-07-04 | 파이브3 제노믹스, 엘엘씨 | 바이러스-연관 종양을 위한 시스템, 방법, 및 조성물 |
| EP3143156B1 (de) | 2014-05-12 | 2020-11-04 | Janssen Pharmaceutica NV | Biologische marker zur identifikation von patienten zur behandlung mit abirateronacetat |
| US11168351B2 (en) | 2015-03-05 | 2021-11-09 | Streck, Inc. | Stabilization of nucleic acids in urine |
| WO2017051542A1 (ja) | 2015-09-24 | 2017-03-30 | 株式会社ヤクルト本社 | 治療法の選択方法およびそれを示すバイオマーカー |
| US20170145475A1 (en) | 2015-11-20 | 2017-05-25 | Streck, Inc. | Single spin process for blood plasma separation and plasma composition including preservative |
| WO2017165803A1 (en) * | 2016-03-24 | 2017-09-28 | President And Fellows Of Harvard College | Compositions and methods that are useful for identifying allele variants that modulate gene expression |
| WO2018022991A1 (en) | 2016-07-29 | 2018-02-01 | Streck, Inc. | Suspension composition for hematology analysis control |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| KR102016216B1 (ko) * | 2017-09-29 | 2019-08-29 | 사회복지법인 삼성생명공익재단 | 위암의 예후 예측용 마커 및 이의 용도 |
| US12378543B2 (en) | 2017-10-19 | 2025-08-05 | Streck Llc | Compositions for hemolysis and coagulation regulation and stabilization of extracellular vesicles |
| ES2963694T3 (es) | 2018-07-10 | 2024-04-01 | Novartis Ag | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteína con dedos de cinc 2 de la familia ikaros (ikzf2) |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1365034A3 (de) * | 2002-05-21 | 2004-02-18 | Bayer HealthCare AG | Verfahren und Zusammensetzungen zur Vorhersage, Diagnose, Prognose, Prävention und Behandlung von malignen Tumoren |
-
2005
- 2005-12-08 AT AT05815265T patent/ATE481504T1/de not_active IP Right Cessation
- 2005-12-08 EP EP05815265A patent/EP1824997B1/de not_active Expired - Lifetime
- 2005-12-08 JP JP2007544813A patent/JP2008524986A/ja active Pending
- 2005-12-08 US US11/792,625 patent/US20090215036A1/en not_active Abandoned
- 2005-12-08 DE DE602005023646T patent/DE602005023646D1/de not_active Expired - Lifetime
- 2005-12-08 WO PCT/EP2005/013141 patent/WO2006061216A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE602005023646D1 (de) | 2010-10-28 |
| JP2008524986A (ja) | 2008-07-17 |
| US20090215036A1 (en) | 2009-08-27 |
| WO2006061216A3 (en) | 2006-12-14 |
| WO2006061216A2 (en) | 2006-06-15 |
| EP1824997A2 (de) | 2007-08-29 |
| EP1824997B1 (de) | 2010-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE481504T1 (de) | Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderung | |
| Lin et al. | Increased expression of long noncoding RNA ABHD11-AS1 in gastric cancer and its clinical significance | |
| ATE550440T1 (de) | Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung | |
| Zhou et al. | Association of long non-coding RNA H19 and microRNA-21 expression with the biological features and prognosis of non-small cell lung cancer | |
| IN2012DN04944A (de) | ||
| ATE398619T1 (de) | Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine | |
| MX2009012722A (es) | Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama. | |
| EA200802242A1 (ru) | Способ определения того, будет или не будет пациент респондером на иммунотерапию | |
| WO2005113816A3 (en) | Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer | |
| WO2007123772A3 (en) | Genes involved in estrogen metabolism | |
| Geyik et al. | Investigation of the association between ATP2B4 and ATP5B genes with colorectal cancer | |
| TW200740844A (en) | Novel MAdCAM antibodies | |
| MX2009010439A (es) | Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama. | |
| WO2014057357A3 (en) | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf | |
| DE602006015966D1 (de) | Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie | |
| WO2005047534A3 (en) | Methods and compositions for the response prediction of malig-nant neoplasia to treatment | |
| Lee et al. | Long noncoding RNA HOTTIP overexpression: a potential prognostic biomarker in prostate cancer | |
| MXPA05014220A (es) | Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos. | |
| WO2006133361A3 (en) | Use of gene expression profiling to predict survival in cancer patient | |
| Jiang et al. | MiR-29c suppresses cell invasion and migration by directly targeting CDK6 in gastric carcinoma. | |
| WO2005119260A3 (en) | Methods for predicting and monitoring response to cancer therapy | |
| Bott et al. | Molecular changes in prostatic cancer | |
| EP1568383A3 (de) | Verwendung eines Oligonukleotide oder seiner aktiven Ableitung für die Zubereitung einer pharmazeutische Zusammensetzung zur Hemmung der Metastasenbildung in Krebsbehandlung | |
| ATE435224T1 (de) | Neue piperidinsubstituierte diaminothiazole | |
| WO2010046530A8 (en) | Methods and uses involving genetic aberrations of nav3 and aberrant expression of multiple genes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |